has agreed to be acquired by

England & Company is pleased to announce that it has served as the exclusive financial advisor to YData Labs, Inc. (“YData” or the “Company”) on its pending acquisition by KPMG US. This transaction deepens England’s Technology footprint advising companies across the Artificial Intelligence (“AI”) and broader IT infrastructure ecosystem.

YData was founded in 2019 to unlock the power of synthetic data to accelerate innovation, ensure privacy, and enable AI through improved quality data. What started as a vision to make data more accessible grew into a platform trusted by teams around the world.

With this acquisition, KPMG will strengthen its AI client offerings, harness synthetic data to enhance AI-enabled client delivery for Audit and Assurance, Tax and Advisory services, and establish a Synthetic Data Center of Excellence designed to accelerate innovation and safeguard client confidentiality.

Gonçalo Martins Ribeiro, Founder and CEO of YData, commented, “England was an exceptional partner throughout this process. Their deep understanding of the AI infrastructure ecosystem and connectivity into key stakeholders coupled with expert process guidance, was instrumental in allowing YData to position the Company to play a key role in how synthetic data will shape the future of AI.”

“In a rapidly evolving AI landscape, synthetic data is playing a key role in testing, training and deploying solutions while balancing privacy, compliance and time-to-value demands,” noted England Managing Director, Joel Strauch. “YData combines a leading-edge platform with deep technical expertise to build, test, and scale synthetic data to support AI. We’re honored to have had the opportunity to partner with the YData team and look forward to seeing their continued success as part of KPMG.”

has been acquired by

England & Company is pleased to announce that NIRx Medical Technologies, LLC (“NIRx”), a pioneer in functional Near-Infrared Spectroscopy (fNIRS) neuroimaging systems and the market leader in this rapidly growing market, has been acquired by Gilde Healthcare Partners BV (“Gilde”), a Netherlands-based healthcare investor specializing medtech, digital health, and therapeutics. NIRx’s systems enable non-invasive, radiation-free, real-time brain imaging for neuroscience research in both lab and natural settings. As part of a strategic combination, Gilde has also acquired Artinis Medical Systems B.V. (“Artinis”), a complementary fNIRS company. This combination creates a global leader in fNIRS and is the foundation for building a market leader in innovative neuroimaging and neuroscience research tools more broadly.

NIRx Group CEO, Richard Barbour, said: “The England team added significant value in negotiating this transaction and bringing it to a successful close. They also went above and beyond with additional financial advisory assistance.” Dr. Patrick Britz, CEO of NIRx GmbH added “It was really a pleasure working with the England team. Their support, attention to detail, diligence, and advice on the deal were instrumental in achieving this amazing result.”

NIRx provides cutting-edge solutions to researchers in human neuroscience to enhance the understanding of the human mind, health, and disease. Through its innovative and comfortable-wearing head gear, NIRx offers a host of integrated technology solutions that support a wide range of investigative aims – from exploring early language acquisition in infants to motor movements in the natural environment to BCI applications or new understandings involving coordinated actions between sensory systems, NIRS imaging solutions from NIRx constitute a comprehensive resource that meet the most demanding applications.

As established leaders in fNIRS, NIRx and Artinis will merge as a newly formed platform within Gilde for neuroimaging and corresponding research tools, all while driving innovation across multiple modalities. The goal of this new platform is to enhance the adoption of fNIRS in applied neuroscience by setting industry standards and making the technology more accessible to academic and institutional researchers globally.

“By bringing both companies together, we are creating a platform that will lead innovation and makes brain imaging tools more accessible to researchers globally,” said Boyd Rutten, Investment Director, Gilde Healthcare.

has been acquired by

December 2024 – England & Company is pleased to announce that it served as the exclusive financial advisor to Xtensible Solutions, LLC (“Xtensible”), a global leader in semantic-based integration and information data management solutions, in its sale to Surveying and Mapping, LLC (“SAM”), a Managed Geospatial Services Company , which focuses on utilities, transportation, and infrastructure clients.

Based in Orlando, Florida, Xtensible has established itself as a prominent leader in standards-based consulting for the utility sector for over two decades. The company is an innovative leader in semantic-based integration and information data management solutions for the utility industry worldwide. Semantic integration permits the sharing and interoperability of data and systems across different platforms, applications, and stakeholders so utilities can more easily apply advanced analytics, machine learning, and automation across their organizational data streams and operational footprint to improve decision-making.

The organization is widely recognized for its innovative Model-Driven Integration (MDi) and Model-Driven Data-Driven Integration (MD3i) software architectural frameworks. SAM is poised to leverage these cutting-edge solutions to enhance its clients’ value.

has agreed to acquire

January 2025 – England & Company is pleased to announce that its client, SGB-SMIT Group (“SGB-SMIT”), a leading independent transformer manufacturer that manufactures capital goods for power supply and is a global market leader with its products, has entered into an agreement to acquire Southwest Electric Co. (“Southwest Electric”), an electrical component manufacturer and service provider. The transaction is expected to close in the first quarter of 2025.

Founded in 1913, SGB-SMIT is headquartered in Regensburg, Germany, and operates 14 locations across eight countries. SGB-SMIT and its affiliate OTC Services in Louisville, Ohio, have served the U.S. market for decades with small, medium, and large power transformers and related services.

has been acquired by

October 2024 – England & Company is pleased to announce that it served as the financial advisor to Sargent Electric Company, LLC (“Sargent”), a leading electrical contractor with over $400 million in annual revenue, in its sale to Constructel Visabeira (“Constructel”), a global leader in providing energy and telecommunications engineering and construction services, backed by Goldman Sachs Alternatives.

Based in Pittsburgh, Pennsylvania, Sargent is a full-service electrical contractor serving Fortune 500 companies throughout the United States.  The company has a long history and proven capabilities in energy transition projects (including renewable energy projects such as wind, solar, renewable natural gas, and battery energy storage), utility transmission, distribution, and substation projects, commercial and industrial projects, and data center projects.

has been acquired by

October 2024 – England & Company is pleased to announce that it served as the exclusive financial advisor to Collagen Solutions, a premier global supplier, developer, and manufacturer of engineered biomaterial-based medical devices and components with applications in regenerative medicine, in its sale to RTI Surgical, a leading contract development and manufacturing organization (“CDMO”) in tissue engineering for regenerative medicine. RTI is a portfolio company of Montagu Private Equity, a leading Europe and U.S.-based private equity firm with $12 billion of assets under management.

“The England & Company team are experts in medical device marketing and contract manufacturing, with extensive relationships in the biomaterials and regenerative medicine spaces. They found us the ideal partner for this business and negotiated strong terms for us,” said Rick Mulford, CEO of Collagen Solutions.

Collagen Solutions provides its OEM customers with high-quality components and fully assembled devices made from medical-grade collagen and xenograft tissue. These devices are used in various therapeutic areas, including cardiovascular, wound care, orthopedics and sports medicine, dental, biosurgery, and neurosurgery. The Company is based in Eden Prairie, MN, and has additional strategically located manufacturing sites in the U.K., New Zealand, and Glencoe, MN.